ReSync Bio to Democratize AI-Powered Drug Discovery with NVIDIA BioNeMo
ReSync Bio, a technology company providing AI-enabled drug discovery solutions, today announced that it has integrated NVIDIA BioNeMo NIM microservices to accelerate its scalable, high throughput AI tools for drug discovery teams. Through this collaboration, ReSync offers seamless, no-code access to the suite of small molecule NVIDIA NIM microservices, empowering drug discovery teams to harness advanced AI without coding expertise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319575218/en/
Image of the ReSync platform showing the integrated output of a partner model from NVIDIA.
The NVIDIA BioNeMo platform provides state-of-the-art AI tools tailored for drug discovery. Its small molecule NIM microservices, such as GenMol for molecular generation and DiffDock for docking predictions, enable researchers to design, optimize, and evaluate molecules with unprecedented speed and accuracy.
The ReSync platform utilizes NVIDIA NIMs for drug discovery by managing the necessary infrastructure and user interfaces for advanced AI models. Working together with NVIDIA, ReSync has integrated NVIDIA’s core small molecule NIM microservices, DiffDock, MolMIM, and GenMol. Combined with other AI models on ReSync’s platform, including ADME and Toxicity predictions, this collaboration allows users to run a full suite of in-silico analysis throughout the Design - Make - Test - Analyze lifecycle. Teams with limited computational resources can now use ReSync to easily run large-scale virtual screening workflows to quickly explore chemical space.
ReSync’s web platform enables customers to store large volumes of virtual compounds securely, run open-source and custom AI models, and track their experimental progress through synthesis and assays. ReSync’s robust queue management and compute scalability provides customers with industry-leading capabilities for AI-enabled drug discovery, enabling a “lab in the loop” with high throughput virtual screening.
As computational demands grow, ReSync ensures that users can access the necessary resources without worrying about infrastructure management. This scalability allows organizations of any size to leverage the full potential of NVIDIA AI tools while focusing on their core research goals.
“AI has transformed digital drug discovery, but many biotechs and pharma remain limited by their ability to deploy and manage AI infrastructure,” said Mihir Trivedi, CEO of ReSync Bio. “Integrating NVIDIA BioNeMo helps bridge this gap by making advanced AI tools accessible to every drug discovery team—no coding required.”
By integrating NVIDIA’s generative AI capabilities, ReSync is poised to help biotechs accelerate drug discovery timelines and reduce development costs for small molecule therapeutics.
ReSync will be showcasing its platform, including using NVIDIA NIM microservices, at the Bio-IT World Conference & Expo from April 2-4, 2025 in Boston, MA at Booth #209.
To learn more about ReSync or request a trial, fill out our contact form here or book a demo here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319575218/en/
Contacts
Media Contact:
Mihir Trivedi
media@resync.bio
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two Young Chefs Have Passed the Japanese Cuisine Certification Exam (Organized by JCDC) and Have Newly Acquired Gold Certification!21.3.2025 15:00:00 CET | Press Release
The Japanese Cuisine and Dietary Culture Development Committee (JCDC) (Location: Minato-ku, Tokyo; Representative: Yoshihiro Murata; Website: https://en.jcdc.tokyo/), which supports and promotes the spread of Japanese food overseas, held a certification exam for foreign chefs in Kyoto. This certification exam is based on the “Guidelines for Certification of Cooking Skills for Japanese Cuisine in Foreign Countries” (enacted on April 1, 2016 / revised on April 1, 2024) established by the Ministry of Agriculture, Forestry and Fisheries (MAFF) of Japan. In this examination, two people from Vietnam, Le Minh Tien and Pham Duc Duy, successfully obtained Gold certification. In addition, the two foreign chefs who came to Japan to participate in the Kyoto final of the “Road to Japanese Culinary Arts Award 2024-2025” hosted by the Japanese Culinary Academy were also certified as Silver. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2025
DEWA’s General Assembly Approves Dividend Payment of AED 3.1 Billion to Shareholders for H2 of 202421.3.2025 14:34:00 CET | Press Release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), reported that its shareholders have, in the general assembly held on 21 March 2025, approved the payment of total dividend of AED 3.1 billion for H2 of 2024, with a record date of 31 March 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250321365368/en/ During DEWA’s General Assembly (Photo: AETOSWire) The meeting, chaired by HE Matar Humaid Al Tayer, Chairman of the Board of Directors of DEWA, was attended by HE Saeed Mohammed Al Tayer, MD & CEO of DEWA, and Members of the Board of Directors of DEWA as well as 92.2% of the shareholders. During the meeting, a Board of Directors was elected for the next three years. For shareholders who are invested in DEWA’s shares prior to the dividend record date of 31 March 2025 (
Ecolab Delivers on Commitments to Save Water in Historic AI Era21.3.2025 12:00:00 CET | Press Release
Water is the world’s most essential resource, and it’s only grown more critical in the age of AI. During this transformative digital revolution, Ecolab, a global sustainability leader that maximizes growth and performance through water solutions and infection prevention services, has continued to meet its goals and work with customers to deliver profitability while advancing optimized water use. By 2030, it is estimated that AI-related growth will demand additional power equivalent to the annual needs of India1 and as much water to meet the annual drinking water needs of the United States2. As the world navigates the growth of AI and high-tech data centers, there is a unique opportunity to leverage AI to help drive efficiency and innovation in circular water management to improve operational processes and conserve natural resources. Ecolab’s mission to help protect water while driving business growth is more important than ever. “The rapid acceleration of AI technology is increasing de
Galderma Publishes its 2024 Annual Report and the Invitation to Its First Annual General Meeting21.3.2025 07:00:00 CET | Press Release
Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published its 2024 Annual Report along with the invitation to its first Annual General Meeting which will be held on April 23, 2025. Galderma’s 2024 Annual Report, the 2024 Finance Report and the invitation to the Annual General Meeting are available on Galderma’s Investor Relations website at https://investors.galderma.com/. About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals
Almirall's 16 th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology21.3.2025 07:00:00 CET | Press Release
Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This year's event features a comprehensive program aimed at sharing state-of-the-art scientific knowledge on skin diseases, their treatment, and clinical best practice. The Skin Academy is a unique opportunity for collaboration, bringing together a broad range of leading experts and clinicians from across the globe to create a network of peers that discuss and learn together to advance the treatment of skin diseases. The event will foster collaboration and co-creation of innovative approaches and solutions to better respond to the unmet needs of the millions of people living with dermatological conditions. Prof. Dr. Ulrich Mrowietz, from the Psoriasis Center at the University Medical Center Schleswig-Holstein, Campus Kielin Germany said: "deep collaboration across experts is essential for advanc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom